This site is intended for health professionals only

Obesity-drug trial “a success”


Orexigen Therapeutics’s experimental obesity drug Contrave has shown weight-loss benefits as well as helping to reduce cholesterol and blood sugar levels, according to a trial.

The company reports that nearly half of patients who completed 56 weeks of treatment lost at least 10% of their weight, with even greater improvement in non-weight loss measures in patients at high risk of heart disease.

This is reflected in data covering secondary measures such as impact on waist circumference, blood lipids, a marker for inflammation and blood sugar levels in a trial of obese diabetics.

The company says three Phase III trials show that Contrave met its primary goal of at least 5% weight loss compared with a placebo, and includes patients who discontinued the medicine at any point.

Contrave is a pill that combines the antidepressant Wellbutrin (bupropion) with a sustained-release version of the opioid blocker naltrexone, which is used to treat alcoholism and other addictions.

Copyright Press Association 2009


Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine